Kezar Life Sciences, Inc. Board of Directors

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Dr. Christopher J. Kirk Ph.D.

Dr. Christopher J. Kirk Ph.D.

Co-Founder, CEO & Director

Mr. Joe Tedrick

Mr. Joe Tedrick

Vice President of Human Resources

Ms. Gitanjali Jain

Ms. Gitanjali Jain

Senior Vice President of Investor Relations & External Affairs

Mr. Zung To

Mr. Zung To

Senior Vice President of Clinical Development

Ms. Pattie Chiang

Ms. Pattie Chiang

Senior VP & Corporate Controller

Mr. Mark Schiller

Mr. Mark Schiller

Chief Legal Officer

Dr. Neel K. Anand Ph.D.

Dr. Neel K. Anand Ph.D.

Senior Vice President of Research & Drug Discovery

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.